Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events

PHASE2CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

December 13, 2022

Primary Completion Date

January 11, 2024

Study Completion Date

July 1, 2024

Conditions
Cardiovascular DiseasesAtherosclerosisLipoprotein(a)
Interventions
DRUG

SLN360

SLN360 is a double-stranded small interfering ribonucleic acid (siRNA) targeting LPA messenger RNA (mRNA)

DRUG

Placebo

Sodium chloride, solution for injection

Trial Locations (29)

Unknown

Royal Adelaide Hospital, Adelaide

Monash Health, Melbourne

Linear Clinical Research, Nedlands

Medicus Services SRO, Brandýs nad Labem

Edumed s.r.o., Kardiologicka, endokrinologicka, diabetologicka a interni ambulance Nachod, Náchod

Pratia Pardubice a.s., Pardubice

Endokrinologie Cerny Most s.r.o., Prague

Gentofte Hospital, Hellerup

Regionshospitalet Godstrup, Herning

Viborg Regional Hospital, Viborg

Academic Medical Center - Department of Vascular Medicine, Amsterdam

Onze Lieve Vrouwe Gasthuis, Amsterdam

Bravis Ziekenhuis - Bergen op Zoom, Roosendaal

Universitair Medisch Centrum Utrecht, Utrecht

VieCuri Medisch Centrum, Venlo

Alian, s.r.o., Kardiologicka ambulancia, Bardejov

Kardiomed s.r.o., Lučenec

Iatros International, Bloemfontein

Tiervlei Trial Centre (TTC), Cape Town

TREAD Research - Department of Cardiology, Cape Town

University of Cape Town - Lipid Laboratory, Cape Town

Paarl Research Centre, Paarl

Dr JM Engelbrecht Trial Site, Somerset West

Helderberg Research Institute, Somerset West

Royal Sussex County Hospital, Brighton

Chelsea and Westminster Hospital, London

Panthera - London North, London

Panthera - Manchester, Rochdale

Panthera - Sheffield, Sheffield

All Listed Sponsors
lead

Silence Therapeutics plc

INDUSTRY